Abemaciclib With or Without Atezolizumab for mCRPC
Status:
Recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and
an immunotherapy drug called atezolizumab, alone or in combination, are effective in
shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing
the safety of the combination of abemaciclib with atezolizumab.